Davis Polk advised UBS AG, Hong Kong Branch, Goldman Sachs (Asia) L.L.C, Morgan Stanley & Co. International plc and Citigroup Global Markets Asia Limited in their capacity as placing agents for the placement of 650,000,000 shares in CSPC Pharmaceutical Group Limited (CSPC) for a total consideration of approximately HK$4.076 billion.   

CSPC is incorporated in Hong Kong with its shares listed on The Stock Exchange of Hong Kong Limited. It is primarily engaged in the manufacture and sale of pharmaceutical products.    

The Davis Polk team included partners Paul Chow and James C. Lin, counsel Faisal Baloch and Peter Cheng and associate Wilson Chan. All members of the Davis Polk team are based in the Hong Kong office.